📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
4 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
BULLISH
TOTAL VIEWS
1
RECENT COVERAGE · 16 ARTICLES
3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market
This article identifies undervalued large-cap equities trading sub-$45 that exhibit strong cash generation characteristics amid elevated...
This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios
Pfizer (PFE) presents a classic dividend trap evaluation scenario, with a 7.27% yield raising questions about sustainability rather than...
China surpassing Europe in Drug Innovation and Development, Pfizer Inc. (PFE) Executive says
Pfizer executives have acknowledged that China is accelerating its pharmaceutical innovation capabilities and is now competitive with...
Pfizer: Why Being Bullish Makes Sense Despite The Patent Cliff (NYSE:PFE)
Pfizer faces a structural headwind common to mature pharma players: patent expirations on blockbuster drugs that historically anchored...
Dividend Roundup: Pfizer, AT&T, Comcast, Sysco, and more
This dividend roundup represents routine corporate capital allocation announcements across diversified sectors including healthcare,...
Nike names former Pfizer CFO David Denton as finance chief
Nike has appointed David Denton, former CFO of Pfizer, to lead its finance function starting August 17. This represents a leadership...
US shoulders disproportionate cost of new medications, report finds
A new Office of Health Policy report quantifies a long-standing structural imbalance: U.S. consumers bear approximately 80% of...
Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead
Pfizer is signaling a strategic pivot away from large-scale acquisitions over the near term, instead directing capital and focus toward...
Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
This analysis compares Pfizer (PFE) and Eli Lilly (LLY) through the lens of dividend yield differentials, highlighting a significant...
Pfizer Inc. (PFE) Discusses New Phase IIb Data and Development Plans for Berobenatide GLP-1 Receptor Agonist in Obesity - Slideshow (NYSE:PFE) 2026-06-17
Pfizer disclosed Phase IIb clinical data for berobenatide, a GLP-1 receptor agonist candidate targeting obesity treatment. This...
Pfizer: Why I'm Still Expecting A Massive Rebound (NYSE:PFE)
Pfizer (PFE) is positioned as a contrarian opportunity with significant upside potential according to analyst commentary. The thesis...
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight
The glioblastoma therapeutic pipeline is experiencing significant expansion with over 220 companies advancing clinical-stage candidates,...
Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
Pfizer's leadership has signaled an inflection point in the company's growth trajectory, suggesting a near-term shift toward...
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.
Bristol Myers Squibb (BMY) is under analyst scrutiny for its dividend sustainability, with a current yield of 4.5% materially above the...
Why Pfizer Stock Popped Today
Pfizer (PFE) experienced upward price movement, driven by analyst or market reassessment of valuation relative to fundamental strength....
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
This comparative analysis examines LXRX and PFE across fundamental dimensions, highlighting a classic risk-return tradeoff between...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice